Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
StockNews.AI · 2 hours
AI Summary
Revolution Medicines announced four data presentations at the ESMO Gastrointestinal Cancers Congress (July 1–4, 2026) in Munich, including two oral zoldonrasib (RMC-9805) studies in 1L and 2L PDAC and two Phase 3 posters for RASolute 303/304. The data explore zoldonrasib with chemotherapy and in combination with daraxonrasib, plus adjuvant daraxonrasib in PDAC. While no results are disclosed yet, positive signals could influence RVMD's valuation and near-term sentiment ahead of potential readouts.
Sentiment Rationale
ESMO data events typically provide sentiment and price sensitivity for biotech names with late-stage or near-term readouts. Positive signals or strong presentations can re-rate growth potential, though actual data are not disclosed yet and results could disappoint. Historical analogs show stock moves around conference data even before ensembling results, especially for PDAC-focused programs with credible KOLs presenting.
Trading Thesis
Near-term catalyst from ESMO data could push RVMD higher if early signals are favorable.
Market-Moving
- ESMO GI Congress presentations scheduled July 1–4, 2026; potential price-moving catalyst.
- Zoldonrasib (RMC-9805) G12D PDAC data in 1L/2L settings; readouts may shift sentiment.
- RASolute 303/304 Phase 3 posters in metastatic and adjuvant PDAC; potential equity impact.
- Overall data evolutions could influence RVMD valuation if safety/efficacy signals improve.
Key Facts
- Revolution Medicines will present four data items at ESMO GI Congress, July 1–4, 2026.
- Two oral zoldonrasib (RMC-9805) PDAC data sets in 1L and 2L settings.
- RASolute 303 and RASolute 304 Phase 3 posters in metastatic and adjuvant PDAC.
- Presentations include zoldonrasib plus chemotherapy and zoldonrasib plus daraxonrasib.
- Positive reads could lift RVMD sentiment ahead of potential clinical readouts.
Companies Mentioned
- Revolution Medicines, Inc. (RVMD): Upcoming ESMO data readouts could influence sentiment and valuation for RVMD.
- RMC-9805 (Zoldonrasib) (RMC-9805): G12D-selective RAS(ON) inhibitor; data to be presented in 1L PDAC.
- RMC-6236 (Daraxonrasib) (RMC-6236): RAS(ON) multi-selective inhibitor; involved in 2L+ combinations and adjuvant program.
Industry News
Category Type: Industry News. It centers on upcoming conference data and pipeline updates, shaping near-term investor perception of RVMD's RAS(ON) programs.